Published in Sangre (Barc) on January 01, 1987
Activities of new quinoline derivatives against genital pathogens. Antimicrob Agents Chemother (1985) 2.51
Comparative in vitro activity of 1-oxa-beta-lactam (LY127935) and cefoperazone with other beta-lactam antibiotics against anaerobic bacteria. Antimicrob Agents Chemother (1980) 2.47
Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation (1997) 2.17
Use of real-time PCR and fluorimetry for rapid detection of rifampin and isoniazid resistance-associated mutations in Mycobacterium tuberculosis. J Clin Microbiol (2000) 2.13
Congenital and acquired thrombotic risk factors in women using oral contraceptives: clinical aspects. Clin Appl Thromb Hemost (2000) 1.99
Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii. J Clin Microbiol (2005) 1.60
Low level of circulating activated protein C is a risk factor for venous thromboembolism. Thromb Haemost (2001) 1.54
Modified test for activated protein C resistance. Lancet (1994) 1.53
Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica (2000) 1.49
The template of the isolated native simian virus 40 transcriptional complexes is a minichromosome. J Mol Biol (1979) 1.47
Mortality and hospital stay related to coagulase-negative Staphylococci bacteremia in non-critical patients. J Infect (2012) 1.46
Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. J Urol (1998) 1.46
[Hemostasis screening in the emergency laboratory]. Sangre (Barc) (1992) 1.39
Human monoclonal antibodies against the rhesus D antigen from women with severe Rh immunization submitted to high-dose intravenous immunoglobulin treatment. Vox Sang (1994) 1.38
Cefoxitin sodium activity against anaerobes: effect of the inoculum size, pH variation and different culture media. J Antimicrob Chemother (1978) 1.32
Rifampin and isoniazid resistance associated mutations in Mycobacterium tuberculosis clinical isolates in Seville, Spain. Int J Tuberc Lung Dis (2002) 1.31
Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia. Eur Respir J (2007) 1.28
Molecular analysis of rifampin and isoniazid resistance of Mycobacterium tuberculosis clinical isolates in Seville, Spain. Tuber Lung Dis (1999) 1.25
Quantitation of transcribing native simian virus 40 minichromosomes extracted from CV1 cells late in infection. J Virol (1981) 1.23
Comparative clinical efficacy of two different single-dose ciprofloxacin treatments for uncomplicated gonorrhea. Sex Transm Dis (1986) 1.21
PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol (2000) 1.10
Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J Clin Invest (1991) 1.08
[Apical hypertrophic myocardiopathy and multiple fistulae between the coronary vessels and the left ventricle]. Rev Esp Cardiol (1995) 1.07
Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment. Blood (1991) 1.05
Two deletions within genes for simian virus 40 structural proteins VP2 and VP3 lead to formation of abnormal transcriptional complexes. J Virol (1981) 1.02
Molecular epidemiology of Mycobacterium tuberculosis strains isolated during a 3-year period (1993 to 1995) in Seville, Spain. J Clin Microbiol (1997) 1.02
Downregulation of human platelet reactivity by neutrophils. Participation of lipoxygenase derivatives and adhesive proteins. J Clin Invest (1993) 1.01
Determination of plasma malondialdehyde-like material and its clinical application in stroke patients. J Clin Pathol (1980) 1.01
Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis. Eur Respir J (1997) 0.99
Characterization of Candida parapsilosis complex isolates. Clin Microbiol Infect (2011) 0.94
Serum malondialdehyde-like material (MDA-LM) in acute myocardial infarction. J Clin Pathol (1983) 0.94
Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood (1994) 0.94
Synergy between cefotaxime, cefsulodin, azlocillin, mezlocillin and aminoglycosides against carbenicillin resistant or sensitive Pseudomonas aeruginosa. J Antimicrob Chemother (1980) 0.92
Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia. Thromb Haemost (1998) 0.91
Expression of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis. Hum Reprod (2003) 0.90
Comparative in-vitro activity of sparfloxacin against genital pathogens. J Antimicrob Chemother (1996) 0.90
Nosocomial outbreak of Pseudomonas aeruginosa endophthalmitis. Infect Control Hosp Epidemiol (2006) 0.89
Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood (1989) 0.89
Spontaneous cervical epidural hematoma associated with oral anticoagulant therapy. Clin Appl Thromb Hemost (2001) 0.88
Intracardiac thrombosis in a case of Behcet's disease associated with the prothrombin 20210G-A mutation. Haematologica (2000) 0.88
Protein C inhibitor and other components of the protein C pathway in patients with acute deep vein thrombosis during heparin treatment. Thromb Haemost (1990) 0.88
Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype. Thromb Haemost (2001) 0.87
Modified sequential multiplex PCR for determining capsular serotypes of invasive pneumococci recovered from Seville. Clin Microbiol Infect (2010) 0.87
Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost (1999) 0.87
Dysfunctional plasminogen in full-term newborn. Pediatr Res (1980) 0.86
Comparative activity of imipenem (N-formimidoyl thienamycin) on enterococci and its interactions with aminoglycosides. J Antimicrob Chemother (1984) 0.86
Homozygous form of the Pelger-Huët leukocyte anomaly in man. Acta Haematol (1981) 0.86
Heterogeneity of human prekallikrein deficiency (Fletcher trait): evidence that five of 18 cases are positive for cross-reacting material. N Engl J Med (1981) 0.86
Functional epitope mapping of insulin-like growth factor I (IGF-I) by anti-IGF-I monoclonal antibodies. Endocrinology (1997) 0.84
Severe inherited "homozygous" protein C deficiency in a newborn infant. Thromb Haemost (1984) 0.84
Prevalence of low HDL cholesterol, and relationship between serum HDL and cardiovascular disease in elderly Spanish population: the PREV-ICTUS study. Int J Clin Pract (2009) 0.84
Diagnostic value of cytokeratin fragment 19 (CYFRA 21-1) in bronchoalveolar lavage fluid in lung cancer. Respir Med (1998) 0.83
Circulating activated protein C is reduced in young survivors of myocardial infarction and inversely correlates with the severity of coronary lesions. J Thromb Haemost (2006) 0.83
Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis. Thromb Haemost (1999) 0.83
Decreased expression of PAI-2 mRNA and protein in pregnancies complicated with intrauterine fetal growth retardation. Thromb Haemost (1996) 0.83
Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease. Am J Pathol (1996) 0.83
Fibrinolytic activity and protein C in preeclampsia. Thromb Haemost (1986) 0.83
mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay. Hum Reprod (2004) 0.82
Participation of tyrosine phosphorylation in cytoskeletal reorganization, alpha(IIb)beta(3) integrin receptor activation, and aspirin-insensitive mechanisms of thrombin-stimulated human platelets. Circulation (2000) 0.82
Inherited fibrinolytic disorder due to an enhanced plasminogen activator level. Thromb Haemost (1984) 0.82
Role of red blood cells in the early stages of platelet activation by collagen. Thromb Haemost (1986) 0.82
Plasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancy. Thromb Haemost (1990) 0.82
Early platelet-collagen interactions in whole blood and their modifications by aspirin and dipyridamole evaluated by a new method (BASIC wave). Thromb Haemost (1985) 0.82
Distribution of lesions in red and fallow deer naturally infected with Mycobacterium bovis. J Comp Pathol (2009) 0.82
Letter: Thromboembolic accidents in patients with congenital deficiency of factor XII. Thromb Diath Haemorrh (1974) 0.81
Global study of viral diarrhea in hospitalized children in Spain: results of structural surveillance of viral gastroenteritis net work (VIGESS-net) 2006-2008. J Clin Virol (2011) 0.81
Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation. Gynecol Obstet Invest (1994) 0.81
Spanish delta-beta-thalassemia: hematological studies and composition of the gamma-chains in ten homozygous patients. Acta Haematol (1983) 0.80
Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia. Am J Obstet Gynecol (1991) 0.80
Changes in molecular forms of prostate-specific antigen during treatment with finasteride. BJU Int (2002) 0.80
Alterations in erythrocyte aggregability in diabetics: the influence of plasmatic fibrinogen and phospholipids of the red blood cell membrane. Clin Hemorheol Microcirc (1998) 0.80
Platelet fatty acids in acute mycoadial infarction. Thromb Res (1979) 0.80
Evaluation of an automated method for the quantification of von Willebrand factor antigen. Its application in the study of vascular dysfunction. Haematologica (2001) 0.80
Reduced fibrinolytic activity in coronary heart disease in basal conditions and after exercise. Thromb Res (1985) 0.80
Letter: Fibrinolytic activity in the endometrial adenocarcinoma. Thromb Diath Haemorrh (1975) 0.80
Identification of high molecular weight derivatives of plasmic digests of cross-linked human fibrin. Thromb Haemost (1978) 0.80
Anaerobic bacteria in men with urethritis. J Eur Acad Dermatol Venereol (1998) 0.79
Red blood cell aggregation and primary hyperlipoproteinemia. Thromb Res (1993) 0.79
Effect of smoking on plasma and platelet fatty acid composition in middle-aged men. Atherosclerosis (1984) 0.79
Acenocoumarol and 6-mercaptopurine: an important drug interaction. Haematologica (1999) 0.79
The determination of MDA as a simple technique for the control of the therapy with aspirin. Thromb Res (1979) 0.79
Abruptio placentae and disseminated intravascular coagulation. Acta Obstet Gynecol Scand (1985) 0.79
Hyperhomocysteinemia, obesity and cryptogenic stroke. Clin Hemorheol Microcirc (2011) 0.79
Quantification of circulating activated protein C in human plasma by immunoassays--enzyme levels are proportional to total protein C levels. Thromb Haemost (1996) 0.79
Sexually transmitted diseases in homosexual males in Seville, Spain. Genitourin Med (1991) 0.79
Unstimulated and thrombin-stimulated platelets binding to immobilized fibrinogen and fibrin on polystyrene supports. Haemostasis (1995) 0.79
Effect of a modified fibrate (Biniwas Retard) on hemorheological alterations in hyperlipemic patients. Clin Hemorheol Microcirc (1999) 0.79
Hemorheological alterations in patients with chronic renal failure. Effect of hemodialysis. Clin Hemorheol Microcirc (1999) 0.79